吃瓜不打烊

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • 吃瓜不打烊 Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • Common Ground
    • Diagnosis: Debt
    • The Body Shops
    • Priced Out
    • Guns, Race, and Profit
    • Broken Rehab
    • Dead Zone
    • Denied
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Medicare Advantage Billing Probe
  • School Vaccine Mandates
  • Weight Loss Drugs Coverage
  • Opioid Settlement Money
  • Abortion Pill Access

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Friday, Jul 7 2017

Full Issue

Opana ER Maker To Withdraw Controversial Opioid Following Rare FDA Request

Pharmaceutical company Endo will voluntarily pull the painkiller, which is about twice as powerful as OxyContin, based on Food and Drug Administration concerns that the drug was too easy to abuse. Other news on the opioid public health crisis comes out of North Carolina, Tennessee and Pennsylvania.

In the end, the executive team at Endo International blinked. The drug maker has voluntarily agreed to withdraw its Opana ER opioid painkiller in response to an unusual request last month from the Food and Drug Administration over concerns the pill is too easily abused. (Silverman, 7/6)

The company said in a statement posted on its website it still believes in the efficacy and safety of Opana ER, or oxymorphone hydrochloride. The FDA said the request was the first time it had asked that an opioid pain medication be pulled because of "the public health consequences of abuse." (Almasy, 7/6)

North Carolina leaders unveiled a multi-part plan last week to combat the rise in opioid overdoses and substance abuse across the state. Gov. Roy Cooper called it 鈥渇lexible鈥 and said it would be updated frequently with new statistics and solutions. The plan calls for everyone to work together, from federal and state lawmakers to law enforcement, local health departments, pharmacists, physicians, businesses, philanthropic groups and community activists. (Knopf, 7/6)

The Mt. Juliet Police Department has equipped officers with聽opioid overdose kits to administer to people or fellow officers. The department purchased 90 kits for individual officers, two kits for K-9 units and two wall-mount kits for just over $6,300, Lt. Tyler Chandler said. (Humbles, 7/6)

By the time Elvis Rosado was 25, he was addicted to opioids and serving time in jail for selling drugs to support his habit.鈥淚 was like, 鈥業 have to kick this, I have to break this,鈥 鈥 he said. For Rosado, who lives in Philadelphia, drugs had become a way to disassociate from 鈥渢he reality that was life.鈥 He鈥檇 wake up physically needing the drugs to function. (Gordon, 7/7)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, August 4
  • Monday, August 3
  • Friday, July 31
  • Thursday, July 30
  • Wednesday, July 29
  • Tuesday, July 28
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • 吃瓜不打烊
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

漏 2026 KFF